Eisai to Launch Parkinson s Disease Treatment Equfina in South Korea
TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai s subsidiary in South Korea, has launched the Parkinson s disease treatment Equfina (safinamide mesilate, safinamide ). This is the first launch of Equfina in the Asian region excluding Japan.
The estimated number of patients with Parkinson s disease is approximately 150,000 in South Korea. Parkinson s disease has high unmet medical needs because of inadequate symptom control using current medications, necessitating new treatment options. This disease is designated as a rare intractable disease in South Korea.
The marketing approval of this drug in South Korea is primarily based on a double-blind, placebo-controlled, Phase III Study (SETTLE study) conducted overseas (including South Korea) to evaluate the efficacy and safety of 24-week oral administration of the once-daily safinamide as an add-on to levodopa in pat